Building a Bridge

Accelerating discovery from lab to patient
The best in the business

The mission of the **Damon Runyon Cancer Research Foundation** is to identify the best early career scientists and encourage them to dedicate themselves to cancer research. Over our 63-year history, we have selected the most brilliant scientists, those with fresh insights and bold ideas. They have gone on to make breakthrough discoveries about the complexities of the human cell and the causes of cancer, and to develop innovative approaches to prevention, diagnosis and treatment of the many forms of this disease.

---

**100% of all donations fund cancer research**

(Overhead is paid through Damon Runyon Broadway Tickets and our endowment)
In this report, we celebrate the 10th anniversary of our Clinical Investigator Award, a groundbreaking program to create an elite group of physicians capable of translating laboratory research into new treatments for patients.

Thanks to the vision of the Damon Runyon Board of Directors and very generous support from Eli Lilly and Company, the Award was established in 2000 to help bridge the “bench to bedside” gap. The Award focuses on physician-scientists who have direct contact with patients, as epitomized by the ‘handshake rule’, which requires that they have personal involvement with patients engaged in their research and clinical trials.

By providing salary and research support, mentorship by leading senior clinical investigators and up to $100,000 in medical school loan repayment, this prestigious program has helped build a new corps of outstanding investigators.

In the past 10 years, we have funded 48 exceptional individuals, a few of whom are highlighted in this report.

The best doctors understand cancer on a personal level.
The best scientists understand cancer on the molecular level.

Those who bridge both roles will accelerate breakthroughs.
WHEN TYLER COLOSIMO FIRST met Dr. Colleen Delaney he had just started his final year of college, but it wasn’t clear that he would finish. Tyler had an aggressive form of Acute Myeloid Leukemia (AML) and his prognosis was “grim.” In AML patients, abnormal white blood cells grow rapidly and accumulate in the bone marrow, interfering with the production of normal blood cells. AML progresses quickly and is typically fatal within weeks or months if left untreated.

Tyler was told that without a bone marrow transplant, his form of AML had a 100% chance of relapse. Additionally, a suitable donor could not be identified – a situation common to approximately 30% of Caucasians and most minority or mixed ethnicity patients. For these patients, umbilical cord blood offers the hope of a cure, and Tyler became the third person to enroll in Dr. Delaney’s experimental cord blood transplant trial.

Like bone marrow, umbilical cord blood contains blood stem cells that can form all the components of our blood and immune system. Also, being “immunologically naive”, cord blood does not require close matching with
the patient, which vastly increases donor options.

However, umbilical cord blood contains only one tenth of the stem cells than that of bone marrow. As a result, there is a significant delay (of up to four weeks after treatment) in the return of the blood system, in particular the white blood cells that fight infection. This is a critically dangerous waiting period for patients, who often encounter severe infections that can be fatal.

Dr. Delaney’s lab uses novel technology that dramatically increases the number of cord blood stem cells available for the patient. On the day of Tyler’s transplant, Dr. Delaney delivered the “expanded” unit herself and stayed by Tyler’s bedside during the infusion, as she does for all of her patients.

Within nine days, Tyler began to show signs of white cell recovery. Within four weeks, he was discharged from the hospital, free of any symptoms of cancer. He has now graduated from college and is hoping to begin teaching English in South Korea in the near future.

“To see Tyler back after two years and looking so good – what’s better than that?” says Dr. Delaney.

Of her Damon Runyon Clinical Investigator Award, Dr. Delaney says:

“The Damon Runyon Award enabled me to ask questions in the lab and then bring them to the bedside. It also enabled me to recruit personnel support that was absolutely vital to move these experiments forward.

From initial concept to where we are now was a six-year process, and it is still continuing. Seeing my patients healthy is what gives me a thrill beyond belief. They are my motivation.”
“ON THE FIRST DAY ROTATING on the pediatric oncology ward as a medical student, I met these kids and their parents and was blown away by their strength in the face of incredibly difficult circumstances.”

Dr. Patrick A. Brown, a pediatric oncologist who also researches childhood leukemias, says, “That, and having a real fascination with leukemia as a disease process, I remember having the gut feeling that I had finally figured out what I wanted to do.”

Dr. Brown sees patients like four-year-old Joshua Czorapinski, who has been battling an acute form of leukemia since he was an infant.

“For decades, patients like Joshua have had to endure years of treatment with chemotherapy. In these high risk cases, chemo tends to be less effective and can have terrible short- and long-term side effects,” Dr. Brown says.

Dr. Brown and his colleagues have developed a promising new drug that selectively targets a gene that drives an acute form of childhood leukemias. Having seen promising results in
Building A Bridge
Accelerating discovery from lab to patient

laboratory models and early adult clinical trials, he is now testing this drug in two national Phase I and II clinical trials of children with acute lymphocytic leukemia (ALL) and acute myelogenous leukemia (AML). He is also devising methods to predict which children are likely to respond to this treatment. Because of the importance of this work, he was recently awarded an additional two years of funding from Damon Runyon.

“With the help of the Damon Runyon Clinical Investigator Award, we have developed this new targeted therapy that we hope will revolutionize treatment for these children by attacking the cancer cells and not the patient’s normal cells.” — Dr. Brown

Ami Czorapinski, Joshua’s mother, says, “So much of what Dr. Brown does is hands-on. As a researcher, he can see the problem and act on it. As a doctor, he knows how to get down to a kid’s level and also how to make parents feel comfortable.

Cancer research has played a huge role in our journey with Joshua, who was diagnosed as an infant. The fact that Dr. Brown could take Joshua’s cells and work on them, and add to the body of knowledge about infant leukemia, is very important. We hope that it will help other parents whose children have this disease.”
Vered Stearns, MD, Damon Runyon-Lilly Clinical Investigator
The Johns Hopkins School of Medicine

“I JOINED DR. STEARNS’ clinical trial simply because I wanted to make sure I gave myself every opportunity to succeed in my health.

And, as a mother of a young daughter, I look to the next generation and want to be part of a process to identify better drugs,” says Mari Kate Connolly, a 34-year-old mother who has an aggressive form of breast cancer.

Dr. Vered Stearns is taking a fresh approach to testing new drug combinations on patients with aggressive breast cancer. Mari Kate is taking part in one of her most recent studies to test a drug that is already approved for lymphoma and may also make breast cancer more susceptible to chemotherapy.

“The traditional approach is to try new drugs or combinations after patients have already had surgery. In these situations, it can be difficult to see the effectiveness of new treatments because the significant mass of cancer cells – the tumor – has been removed.”
“In some cases, we can test new therapies before the tumor is removed. In this way we can see changes in the tumor within the breast itself. This is what my clinical trials are focused on now – testing promising combinations and utilizing this approach to see clearly and quickly what works,” says Dr. Stearns.

Since receiving the Clinical Investigator Award in 2000, Dr. Stearns has led more than 20 breast cancer studies. Her work has identified new, promising drug combinations and has great potential to significantly improve therapy regimens for breast cancer patients.

“We need to try new ideas to make progress, and if there is a drug that could give me a couple of extra percentage points (towards survival), then I’ll take it,” says Mari Kate.

“Knowing that Dr. Stearns is a researcher is a huge benefit, as she can talk firsthand about the studies. There’s a sense of passion, a real desire to make advances. She also has a genuine care for me as a patient. I feel fortunate to be with her.”

Dr. Stearns, who was part of the inaugural group of Damon Runyon Clinical Investigators, added, “The Foundation has been enormously helpful in giving me and other physician-scientists protected time to balance research and clinical work. It gave me flexibility and also offered some repayment of my medical school loan, and this was very important in keeping me in the academic setting.

“My patients motivate me to do better – they drive me to do the research. Also, the observations that patients and their families make help to generate new research questions. So the connection is essential for translational research.”
In the decade since its founding, the Clinical Investigator Award has supported studies and clinical trials that have made a significant impact in the field of cancer research. More importantly, this work is already helping cancer patients.

Some of these outstanding discoveries are highlighted here:

**Immunotherapy Breakthrough**

Cure of advanced-stage melanoma using the patient’s own immune cells.

*Cassian Yee, MD*, Fred Hutchinson Cancer Research Center

**Pioneering Cancer Stem Cell Research in Brain Tumors**

Determining why cancer stem cells are resistant to treatment and finding new ways to make them vulnerable.

*Jeremy N. Rich, MD*, Cleveland Clinic

**New Skin Cancer Vaccine**

Developed immunotherapy-based melanoma vaccine that is approved for canine use and is currently being tested in humans.

*Jedd D. Wolchok, MD, PhD*, Memorial Sloan-Kettering Cancer Center

**HPV Identified as a Cause of Head-And-Neck Cancer**

Establishment of the human papillomavirus (HPV) as a cause of head-and-neck cancers, and discovery that HPV-related cancers respond to treatment differently than non-HPV-related cancers.

*Maura L. Gillison, MD, PhD*, The Ohio State University

**Making Personalized Medicine a Reality**

Development of a new technique that could allow cancer patients to receive personalized treatments based on genetic profiles of their own tumors, decreasing unwanted side effects and improving cure rates.

*Scott A. Armstrong, MD, PhD*, Dana-Farber Cancer Institute and *William R. Sellers, MD*, Novartis Institutes for Biomedical Research
Board of Directors

**CHAIRMAN**
Mr. Dale F. Frey  
Retired Chairman of the Board  
and President  
General Electric Investment Corporation  
Stamford, Connecticut

**VICE CHAIRMAN, SCIENTIFIC PROGRAMS**
David M. Livingston, MD  
Deputy Director  
 Dana-Farber/Harvard Cancer Center  
Emil Frei III Professor  
Harvard Medical School  
Boston, Massachusetts

**VICE CHAIRMAN, FINANCE AND TREASURER**
Mr. Leon G. Cooperman  
Chairman and CEO  
Omega Advisors, Inc.  
New York, New York

**VICE CHAIRMAN, BOARD DEVELOPMENT**
Mr. Kenneth G. Langone  
Chairman and Managing Director  
Invemed Associates, Inc.  
New York, New York

**VICE CHAIRMAN, AUDIT AND CORPORATE GOVERNANCE AND SECRETARY**
Sanford W. Morhouse, Esq.  
Of Counsel  
Dewey & LeBoeuf LLP  
New York, New York

Mr. David M. Beirne  
Partner  
Benchmark Capital  
Menlo Park, California

Steven J. Burakoff, MD  
Director, The Tisch Cancer Institute  
Mount Sinai Medical Center  
New York, New York

William L. Carroll, MD  
Director  
NYU Cancer Institute  
New York, New York

Mr. Gary E. Erlbaum  
President  
GreenTree Properties  
Ardmore, Pennsylvania

Thomas J. Fahey, Jr., MD  
Senior Vice President for Clinical Program Development  
Director, International Center  
Memorial Sloan-Kettering Cancer Center  
New York, New York

Mr. John A. Fry  
President  
Franklin & Marshall College  
Lancaster, Pennsylvania

Elaine V. Fuchs, PhD  
Rebecca C. Lancefield Professor  
Laboratory Head  
The Rockefeller University  
New York, New York

Richard B. Gaynor, MD  
Vice President  
Cancer Research and Clinical Investigation  
Eli Lilly and Company  
Indianapolis, Indiana

Ms. Margaret A. Gilliam  
President  
Gilliam & Company  
New York, New York

Todd R. Golub, MD  
Director, Cancer Program  
The Broad Institute of MIT and Harvard  
Cambridge, Massachusetts

Mr. Michael L. Gordon  
Chief Operating Officer  
Angelo, Gordon & Company LP  
New York, New York

Mr. Scott Greenstein  
President  
Entertainment and Sports  
Sirius Satellite Radio, Inc.  
New York, New York

Mr. Jay W. Ireland  
President and CEO  
GE Asset Management  
Stamford, Connecticut

Mr. Alan M. Leventhal  
Chairman and CEO  
Beacon Capital Partners, LLC  
Boston, Massachusetts

Ronald Levy, MD  
Chief, Division of Oncology  
Professor of Medicine  
Stanford University School of Medicine  
Stanford, California

Anthony F. Lofrisco, Esq.  
Retired Partner  
Winston & Strawn  
New York, New York

Mr. David G. Marshall  
Chairman and CEO  
Amerimar Realty Company  
Philadelphia, Pennsylvania

Mr. John H. Myers  
Senior Advisor  
Angelo, Gordon & Company LP  
New York, New York

Richard J. O’Reilly, MD  
Chair, Department of Pediatrics  
Chief, Pediatric Bone Marrow Transplant Service  
Claire L. Tow Chair in Pediatric Oncology Research  
Memorial Sloan-Kettering Cancer Center  
New York, New York

Mrs. Katharine F. Plum  
Hobe Sound, Florida

Mr. Andrew S. Rachleff  
Partner  
Benchmark Capital  
Menlo Park, California

Ms. Karen D. Seitz  
Managing Director  
Goldman, Sachs & Co  
New York, New York

Samuel C. Silverstein, MD  
John C. Dalton Professor  
Department of Physiology and Cellular Biophysics  
Columbia University  
New York, New York

Mr. Robert C. Wright  
Senior Advisor  
Lee Equity Partners LLC  
Co-founder, Autism Speaks  
New York, New York

**EMERITUS BOARD MEMBERS**
Sidney Altman, PhD  
Sterling Professor of Biology  
Yale University  
New Haven, Connecticut

David Baltimore, PhD  
President Emeritus and Robert Andrews Millikan Professor of Biology  
California Institute of Technology  
Pasadena, California

Mrs. Connie Lurie  
The Lurie Company  
San Francisco, California

I. George Miller, MD  
John P. Enders Professor of Pediatric Infectious Diseases  
Professor of Epidemiology and Molecular Biophysics and Biochemistry  
Yale University School of Medicine  
New Haven, Connecticut

Henry C. Pitot, MD, PhD  
Professor Emeritus of Oncology and Pathology  
McArdle Laboratory for Cancer Research  
Madison, Wisconsin

Mrs. Virginia Ueberroth  
The Ueberroth Family Foundation  
Laguna Beach, California

Robert C. Young, MD  
Chancellor  
Fox Chase Cancer Center  
Philadelphia, Pennsylvania

**EXECUTIVE DIRECTOR**
Lorraine W. Egan, Esq.
Damon Runyon Fellowship Award
Supports the training of the brightest postdoctoral scientists as they embark upon their research careers. The funding enables them to be mentored by established investigators in leading research laboratories across the country.

**THREE-YEAR AWARD**
Basic Scientists: $140,000
Physician-Scientists: $174,000

Damon Runyon Clinical Investigator Award
Supports early career physician-scientists conducting patient-oriented research. The goal of this innovative program is to increase the number of physicians capable of moving seamlessly between the laboratory and the patient’s bedside in search of breakthrough treatments.

**THREE- TO FIVE-YEAR AWARD**
$450,000 to $750,000 plus up to $100,000 for medical school loan repayment.

**Continuation Grant**
Supports Damon Runyon Clinical Investigators who are approaching the end of their original three-year awards and need extra time and funding to complete a promising avenue of research or initiate/continue a clinical trial.

**TWO-YEAR AWARD**
$300,000

* This program, initiated this year, is possible through the generous support of the William K. Bowes, Jr., Foundation, and Connie and Robert Lurie.

Damon Runyon-Rachleff Innovation Award
Supports the next generation of exceptionally creative thinkers with high-risk, high-reward ideas that have the potential to significantly impact our understanding of and/or approaches to the prevention, diagnosis or treatment of cancer.

**THREE-YEAR AWARD**
$450,000

*This program is supported by a founding grant from Andy and Debbie Rachleff.*
Damon Runyon Fellowship
Award Committee 2009

CHAIR
(5/08-5/09)
David J. Julius, PhD
Morris Herzstein Chair in Molecular Biology and Medicine
Professor and Chair of Physiology
University of California, San Francisco
San Francisco, California

CHAIR
(11/09-5/10)
Rama Ranganathan, MD, PhD
Professor, Department of Pharmacology
Cecil H. and Ida Green Chair in Biomedical Science
Director, Green Center for Systems Biology
University of Texas Southwestern Medical Center
Dallas, Texas

Victor R. Ambros, PhD
Professor, Program in Molecular Medicine
University of Massachusetts Medical School
Worcester, Massachusetts

Adam P. Arkin, PhD
Professor, Bioengineering and Chemistry
Department of Bioengineering
University of California, Berkeley
Berkeley, California

David P. Bartel, PhD
Investigator, Howard Hughes Medical Institute
Professor of Biology
Massachusetts Institute of Technology
Member
Whitehead Institute for Biomedical Research
Cambridge, Massachusetts

Lynn Cooley, PhD
Professor of Genetics, Cell Biology and Molecular, Cellular and Developmental Biology
Department of Genetics
Yale University School of Medicine
New Haven, Connecticut

Benjamin F. Cravatt, III, PhD
Professor and Chair
Department of Chemical Physiology
The Skaggs Institute for Chemical Biology
Helen L. Dorris Institute for the Study of Neurological and Psychiatric Disorders
The Scripps Research Institute
La Jolla, California

Andrew G. Dillin, PhD
Investigator, Howard Hughes Medical Institute
Pioneer Developmental Chair
Molecular and Cell Biology Lab
Salk Institute for Biological Studies
La Jolla, California

Robert N. Eisenman, PhD
Member, Basic Sciences Division
Fred Hutchinson Cancer Research Center
Seattle, Washington

Sankar Ghosh, PhD
Silverstein and Hut Family Professor of Microbiology
Chair, Department of Microbiology
Columbia University
New York, New York

Daniel E. Gottschling, PhD
Member, Basic Sciences Division
Fred Hutchinson Cancer Research Center
Seattle, Washington

Marnie E. Halpern, PhD
Staff Scientist
Department of Embryology
Carnegie Institution for Science
Baltimore, Maryland

Tyler Jacks, PhD
Investigator, Howard Hughes Medical Institute
Director, David H. Koch Institute for Integrative Cancer Research
David H. Koch Professor of Biology
Ludwig Scholar
Massachusetts Institute of Technology
Cambridge, Massachusetts

Guillermina (Gigi) Lazano, PhD
Matti A. Kallio Research Chair
Professor and Section Chief
Department of Molecular Genetics
M.D. Anderson Cancer Center
The University of Texas
Houston, Texas

Liquan Luo, PhD
Investigator, Howard Hughes Medical Institute
Professor, Department of Biological Sciences
Stanford University
Stanford, California

Philippa C. Marrack, FRS, PhD
Investigator, Howard Hughes Medical Institute
Department of Immunology
National Jewish Medical and Research Center
Denver, Colorado

David J. McConkey, PhD
Director of Urologic Research
Professor of Urology
M.D. Anderson Cancer Center
The University of Texas
Houston, Texas

Lee A. Niswander, PhD
Investigator, Howard Hughes Medical Institute
Professor, Department of Pediatrics
Section of Developmental Biology
University of Colorado Denver
Aurora, Colorado

Ramon E. Parsons, MD, PhD
Avon Foundation Professor of Medicine and Pathology
Institute for Cancer Genetics
Assistant Director of Neuro-Oncology
Herbert Irving Cancer Center
Columbia University
New York, New York

Norbert Perrimon, PhD
Investigator, Howard Hughes Medical Institute
Professor of Genetics
Harvard Medical School
Boston, Massachusetts

Jim M. Roberts, MD, PhD
Director, Basic Sciences Division
Fred Hutchinson Cancer Research Center
Seattle, Washington

Martine F. Roussel, PhD
Member
Department of Tumor Cell Biology and Genetics
St. Jude Children’s Research Hospital
Memphis, Tennessee

Amita Sehgal, PhD
Investigator, Howard Hughes Medical Institute
Professor, Department of Neuroscience
University of Pennsylvania School of Medicine
Philadelphia, Pennsylvania

Andrey S. Shaw, MD
Investigator, Howard Hughes Medical Institute
Emil R. Unanue Professor of Immunobiology
Department of Pathology and Immunology
Washington University
St. Louis, Missouri

Wilfred A. van der Donk, PhD
Investigator, Howard Hughes Medical Institute
Richard E. Heckert Professor of Chemistry
Department of Chemistry
University of Illinois, Urbana-Champaign
Urbana, Illinois

Johannes Walter, PhD
Associate Professor
Department of Biological Chemistry and Molecular Pharmacology
Harvard Medical School
Boston, Massachusetts

Accelerating discovery from lab to patient
Damon Runyon Fellowship Awards

CALIFORNIA

Lu Gan, PhD
“Electron cryotomography of a eukaryotic nucleus” with Grant J. Jensen, PhD, California Institute of Technology, Pasadena

Maya Capelson, PhD
“Investigation into the role of the nucleolus complex in chromatin function” with Martin W. Hetzer, PhD, Salk Institute for Biological Studies, La Jolla

Sharsti L. Sandall, PhD *
“Mechanisms regulating maintenance of stem cells and the niche in Drosophila” with D. Leanne Jones, PhD, Salk Institute for Biological Studies, La Jolla

Sarah E. Tully, PhD
Conrad Hilton Fellow
“A functional proteomic strategy to characterize endocannabinoid biosynthetic enzymes” with Benjamin F. Cravatt, III, PhD, The Scripps Research Institute, La Jolla

Sean C. Bendall, PhD *
“Improved single-cell phospho-protein signaling analysis of oncogenic progression in leukemia” with Garry P. Nolan, PhD, Stanford University, Stanford

Won-Suk Chung, PhD *
“Heterogeneity of astrocytes in their origins and regenerative potentials” with Ben A. Barnes, MD, PhD, Stanford University, Stanford

Liana F. Lareau, PhD *
Howard Hughes Medical Institute Fellow
“Global analysis of the role of 5’ untranslated regions in the regulation of translation” with Patrick O. Brown, MD, PhD, Stanford Institute for Biological Studies, La Jolla

Benjamin R. Myers, PhD *
“Analyzing the mechanism of Hedgehog signaling regulation by the Patched protein” with Philip A. Beachy, PhD, Stanford University, Stanford

Cara T. Pager, PhD
Robert Black Fellow
“The role of liver-specific microRNA-122 in Hepatitis C virus gene expression” with Peter Sarnow, PhD, Stanford University, Stanford

Yu Wong, MD, PhD *
Howard Hughes Medical Institute Fellow
“Development of novel T cell repertoire assay for the study of the immune response to breast cancer” with Mark M. Davis, PhD, Stanford University, Stanford

Xiaomeng Milton Yu, PhD
“Investigating the mechanisms that determine localized axon degeneration during Drosophila mushroom body γ-neuron pruning” with Liqun Luo, PhD, Stanford University, Stanford

Michael D. Gordon, PhD
“Taste circuits and motor control in Drosophila melanogaster” with Kristin Scott, PhD, University of California, Berkeley

Chitra V. Kotwaliwale, PhD
Howard Hughes Medical Institute Fellow
“Regulation of meiotic chromosome behavior in Caenorhabditis elegans” with Abby F. Dernburg, PhD, University of California, Berkeley

Sarah E. Siegrist, PhD
Robert Black Fellow
“Mechanisms of adult neurogenesis in Drosophila melanogaster” with Iswar K. Hariparan, MBBS, PhD, University of California, Berkeley

Karsten H. Siller, PhD
“Mechanisms of homeostatic synaptic scaling” with Lu Chen, PhD, University of California, Berkeley

Hayan Yoon, PhD
“GABAergic inhibition in drug addiction and reward-dependent learning” with Mu-Ming Poo, PhD, University of California, San Francisco

Orkun Akin, PhD *
Howard Hughes Medical Institute Fellow
“Identification and characterization of Drosophila Dscam cytoplasmic domain binding partners” with S. Lawrence Zipursky, PhD, University of California, Los Angeles

Christopher S. Campbell, PhD *
“Control of the chromosomal passenger complex by post-translational modification” with Arshad B. Desai, PhD, University of California, San Diego

Erhu Cao, PhD
“Structure and physiology of sensory TRP channels” with David J. Julius, PhD, University of California, San Francisco

Lee Stirling Churchman, PhD
Merk Fellows
“Exploring mammalian endocytic pathways using quantitative RNAi-based genetic interaction maps” with Jonathan S. Weissman, PhD, University of California, San Francisco

Gianna Elena Hammer, PhD
Robert Black Fellow
“Coordination of dendritic cell maturation and immune responses by the ubiquitin modifying enzyme A20” with Averil Ma, MD, University of California, San Francisco

Thomas M. Huckaba, PhD
Howard Hughes Medical Institute Fellow
“Identification and characterization of tubulin acetylace” with Ronald D. Vale, PhD, University of California, San Francisco

Rebecca A. Irie, PhD
“Ionic decoding signaling pathway interactions in brain tumor suppression” with Arturo Alvarez-Buylla, PhD, University of California, San Francisco

Melissa R. Junttila, PhD
Enrique Cepeda, PhD, Fellow
“Re-designing p53-mediated tumor suppression” with Gerard J. Evan, PhD, University of California, San Francisco

Krista Kaasik, PhD
“Characterization of GSK3 dependent circadian phosphoproteome-relevance for tumor genesis” with Ying-Hui Fu, PhD, and Louis J. Ptáček, MD, University of California, San Francisco

Guangshuo Ou, PhD
“Cellular events underlying organ repair in planaria” with Ronald D. Vale, PhD, University of California, San Francisco

Avi Priel, PhD
“Investigating the kinetic mechanism of hedgehog signaling in the mammalian nervous system” with David J. Julius, PhD, University of California, San Francisco

Timothy O. Street, PhD
Connie and Bob Lurie Fellow
“Investigating the physical basis of substrate interaction with the HSP90 protein chaperone” with David J. Julius, PhD, University of California, San Francisco

Jesse Zalatan, PhD *
“Elucidating the kinetic mechanism by which a scaffold protein regulates MAPK signaling” with Wendell A. Lim, PhD, University of California, San Francisco

COLORADO

Jianfu (Jeff) Chen, PhD *
Howard Hughes Medical Institute Fellow
“The role of flotol acid in the maintenance of X inactivation” with Lee A. Niswander, PhD, University of Colorado Denver, Aurora
CONNECTICUT
Jelena Bezbradica, PhD
Howard Hughes Medical Institute Fellow
“Molecular basis for transcription-independent cytokine regulation of immune responses” with Ruslan M. Medzhitov, PhD, Yale University, New Haven

Oscar R. Colegio, MD, PhD†* “Defining the role of the innate immune system in tumor progression and metastasis” with Ruslan M. Medzhitov, PhD, Yale University, New Haven

Kristina M. Herbert, PhD* How ard Hughes Medical Institute Fellow
“Regulation and mechanism of pri-miRNA processing by Drosha and DGCR8” with Joan A. Steitz, PhD, Yale University, New Haven

Heather M. Scobie, PhD Fayez Sarofim Fellow
“Defining the functional interface between Campylobacter jejuni and its mammalian host cells” with Jorge E. Galán, PhD, DVM, Yale University, New Haven

ILLINOIS
Brian J. Yeh, PhD “Determining how a conserved signaling network establishes cell fate asymmetry” with Eric L. Weiss, PhD, Northwestern University, Chicago

MARYLAND
Mary G. Goll, PhD “Genetic analysis of transcriptional silencing in the vertebrate brain” with Marrie E. Halpern, PhD, Carnegie Institution for Science, Baltimore

Chuan-Hsiang Huang, MD, PhD* Harold L. Ploetck Fellow “Adaptation and gradient amplification in the chemotaxis signaling pathway” with Peter N. DeVreotes, PhD, The Johns Hopkins University, Baltimore

MASSACHUSETTS
Alexandra M. Deaconescu, PhD Howard Hughes Medical Institute Fellow “Elucidation of the mechanism of transcription-DNA repair coupling” with Nikolaus Grigorieff, PhD, Brandeis University, Waltham

Michael J. Emanuele, PhD Philip O’Bryan Montgomery, Jr., MD, Fellow “Identification and characterization of proteins with altered stabilities in response to DNA damage” with Stephen J. Elledge, PhD, Brigham and Women’s Hospital, Boston

Xu Tan, PhD* “Study of the BRCA1 A complex in DNA damage response” with Stephen J. Elledge, PhD, Brigham and Women’s Hospital, Boston

Akinwumi I. Ojseina, MBBS, PhD Rebecca Ridley Kry Fellow “Pathogen discovery and genomic characterization of infection-associated lymphomas” with Matthew Meyerson, MD, PhD, Dana-Farber Cancer Institute, Boston

Eric J. Bennett, PhD “Deubiquitylating enzymes as molecular regulators of oncogenesis” with J. Wade Harper, PhD, Harvard Medical School, Boston

Jason Michael Crawford, PhD* “Systematic approaches to discovering bioactive bacterial metabolites” with Jon Clardy, PhD, Harvard Medical School, Boston

Lea A. Goentoro, PhD Robert Black Fellow “Toward a systems-level understanding of the canonical Wnt signaling pathway” with Marc W. Kirschner, PhD, Harvard Medical School, Boston

Simon Jenni, PhD* Howard Hughes Medical Institute Fellow “Structural and functional studies of kinetochore” with Stephen C. Harrison, PhD, Harvard Medical School, Boston

Young Kwon, PhD* “Identification and validation of negative regulators in insulin signaling” with Norbert Perrimon, PhD, Harvard Medical School, Boston

Yunsun Nam, PhD “Structural and biochemical studies of protein translocation mediated by SecA and SecYEG” with Tom A. Rapoport, PhD, Harvard Medical School, Boston

Elisabeth S. Sattely, PhD “Bioisotopes: characteristics of specific bonds between heteroatomic: mechanistic understanding for the development of novel therapeutics” with Christopher T. Walsh, PhD, Harvard Medical School, Boston

Ian Wapinski, PhD* Howard Hughes Medical Institute Fellow “Unraveling the costs and benefits of gene expression on cellular growth” with Roy Kishony, PhD, Harvard Medical School, Boston

William J. Greenleaf, PhD* “Fluorogenic single-molecule fluorescence enzymology” with X. Sunney Xie, PhD, Harvard University, Cambridge

Yoh Isogai, PhD “Molecular mechanisms of innate defensive behaviors in rodents” with Catherine Dulac, PhD, Harvard University, Cambridge

László Kürti, PhD “Synthesis of antiangiogenic steroidal alkaloids, Cortistatin A, and preparation of potentially active analogs” with Elias James Corey, PhD, Harvard University, Cambridge

Josselin Milloz, PhD* “Coordination of quiescence, meiosis and autophagy in the yeast Saccharomyces cerevisiae” with Sharad Ramanathan, PhD, Harvard University, Cambridge

Melanie A. Samuel, PhD “Molecular basis of age-related synaptic disorganization” with Joshua R. Sanes, PhD, Harvard University, Cambridge

Shengin Yao, PhD Howard Hughes Medical Institute Fellow “Identification of neuronal circuits mediating innate aggressive behavior in mouse” with Catherine Dulac, PhD, Harvard University, Cambridge

Sarah K. Bowman, PhD “Characterization of nucleosome positioning in Polycomb-mediated gene repression” with Robert E. Kingston, PhD, Massachusetts General Hospital, Boston

Daniel H. Kim, PhD* “Epigenetic regulation of X-chromosome inactivation by noncoding RNAs” with Jeannie T. Lee, MD, PhD, Massachusetts General Hospital, Boston

Ken S. Lau, PhD* Robert Black Fellow “Elucidation of a novel signaling network downstream of KRas in colorectal cancer” with Kevin M. Haigis, PhD, and Douglas A. Lauffenburger, PhD, Massachusetts General Hospital, Boston

Taioa A. Montgomery, PhD* “Mechanisms of microRNA-directed RNA silencing” with Gary B. Ruvkun, PhD, Massachusetts General Hospital, Boston

Carolyn M. Phillips, PhD Marion Abbe Fellow “Characterization of chromatin-associated factors in small RNA pathways” with Gary B. Ruvkun, PhD, Massachusetts General Hospital, Boston

Yimon Aye, PhD* “Investigations towards mechanistic understanding of human ribonucleotide reductase β-subunit-specific inhibition by triapine” with JoAnne Stubbe, PhD, Massachusetts Institute of Technology, Cambridge

Robert K. Bradley, PhD* “Investigating the splicing co-regulatory network” with Christopher B. Burge, PhD, Massachusetts Institute of Technology, Cambridge
Nadya Dimitrova, PhD *  
Robert Blount Family Fellow  
“Functional characterization of the role of p53-regulated lncRNAs in tumorigenesis” with Tyler Jacks, PhD, Massachusetts Institute of Technology, Cambridge

Ryan C. Heller, PhD  
Howard Hughes Medical Institute Fellow  
“Analysis of initial stages of the activation of replication origins in Saccharomyces cerevisiae” with Stephen P. Bell, PhD, Massachusetts Institute of Technology, Cambridge

Adam G.W. Matthews, PhD  
Fraternal Order of Eagles Fellow  
“Defining the architecture of human DNA replication origins” with Stephen P. Bell, PhD, Massachusetts Institute of Technology, Cambridge

William Rodney Hardy, PhD *  
“Eucodion of signal transduction pathways controlling oncogene-induced senescence and their protective roles against melanoma and breast cancer” with Michael R. Green, MD, PhD, University of Massachusetts Medical School, Worcester

Elaine M. Youngman, PhD  
Kenneth G. and Elaine A. Langone Fellow  
“Analysis of the biogenesis and functions of endogenous small RNAs in Caenorhabditis elegans” with Craig C. Mello, PhD, University of Massachusetts Medical School, Worcester

Daniel F. Jarosz, PhD  
Howard Hughes Medical Institute Fellow  
“The influence of Hsp90 on the relationship between genotype and phenotype” with Susan L. Lindquist, PhD, Whitehead Institute for Biomedical Research, Cambridge

Jared T. Nordman, PhD *  
Howard Hughes Medical Institute Fellow  
“Cell cycle control of DNA replication in metazoans” with Terry L. Orr-Weaver, PhD, Whitehead Institute for Biomedical Research, Cambridge

Alla A. Sigova, PhD  
Robert Black Fellow  
“Genetic and epigenetic mechanisms of maintaining the embryonic stem cell identity” with Richard A. Young, PhD, Whitehead Institute for Biomedical Research, Cambridge

MISSOURI

Ken Cadwell, PhD  
Lallage Feazel Wall Fellow  
“Characterization of mice deficient in autophagy protein ATG16L1” with Herbert W. Virgin, IV, MD, PhD, Washington University, St. Louis

Tiffany A. Reese, PhD *  
“The immune response to latent gamma herpesvirus infection” with Herbert W. Virgin, IV, MD, PhD, Washington University, St. Louis

NEW JERSEY

Michelle M. Boehm, PhD  
Howard Hughes Medical Institute Fellow  
“Understanding the molecular mechanisms of proaryotic/eukaryotic communication” with Bonnie L. Bassler, PhD, Princeton University, Princeton

Yun Wu, PhD  
Robert Black Fellow  
“Investigation of the activation mechanism of telomerase by Est3p in Saccharomyces cerevisiae” with Virginia A. Zakian, PhD, Princeton University, Princeton

NEW YORK

Esteban O. Mazzoni, PhD  
Berger Foundation Fellow  
“Taking on SSA, a mutagenic DNA repair pathway induced in familial-inherited breast cancer” with Hynek Wichterle, PhD, Columbia University, New York

Katharina Schlacher, PhD  
“Establishment of antero-posterior pattern of Hox gene expression in ES cell-derived motor neurons” with Virginia A. Zakian, PhD, Princeton University, Princeton

Lu Bai, PhD  
Suzanne and Bob Wright Fellow  
“Nuclear pore complex scaffold” with Bruce A. Edgar, PhD, Fred Hutchinson Cancer Research Center, Seattle

Laura A. Banaszynski, PhD  
Angelo Family Fellow  
“Investigating the epigenetic nature of histone modifications” with C. David Allis, PhD, The Rockefeller University, New York

Emily A. Foley, PhD  
Harry and Mary Stein Fellow  
“Examining the role of mitotic kinases in mitotic slippage using phospho-sensors and chemical inhibitors” with Tarun M. Kapoor, PhD, The Rockefeller University, New York

Jung-Min Kee, PhD *  
Leo and Lilyan Cole Fund Fellow  
“Investigation of histidine phosphorylation in histone H4 through synthetic protein chemistry” with Thomas W. Muir, PhD, The Rockefeller University, New York

NORTH CAROLINA

David Q. Matus, PhD  
Robert Black Fellow  
“Unraveling the gene regulatory network underlying anchor cell invasion” with David R. Sherwood, PhD, Duke University, Durham

OREGON

Sunny D. Gilbert, PhD  
“Mechanisms of RNA silencing selectivity” with James C. Carrington, PhD, Oregon State University, Corvallis

Christopher A. Johnston, PharmD, PhD  
Dennis and Marsha Dannerman Fellow  
“Implementation of a novel system in Drosophila S2 cells for investigating asymmetric cell division” with Kenneth E. Prehoda, PhD, and Chris Q. Doe, PhD, University of Oregon, Eugene

PENNSYLVANIA

Kathryn E. Wellen, PhD  
“Role of hexosamine signaling in linking metabolism and growth control” with Craig B. Thompson, MD, University of Pennsylvania, Philadelphia

TENNESSEE

Matthew F. Calabrese, PhD *  
Howard Hughes Medical Institute Fellow  
“Ubiquitin interactions with a novel ubiquitin recognition motif” with Brenda A. Schuman, PhD, St. Jude Children’s Research Hospital, Memphis

WASHINGTON

Tao Wang, PhD  
“Dissection of the TSC/Rheb/TOR pathway in cell growth control” with Bruce A. Edgar, PhD, Fred Hutchinson Cancer Research Center, Seattle

Danielle S.W. Benoit, PhD  
Merck Fellow  
“Intracellularly targeted siRNA delivery vehicles for cancer therapies” with Patrick S. Stayton, PhD, University of Washington, Seattle

* Initial Award  
† Physician-Scientist
Damon Runyon-Rachleff
Innovation Award Committee 2009

CHAIR
Ronald Levy, MD
Chief, Division of Oncology
Professor of Medicine
Stanford University Medical Center
Stanford, California

Elizabeth H. Blackburn, PhD
Morris Herzstein Professor of Biology and Physiology
Department of Biochemistry and Biophysics
University of California, San Francisco
San Francisco, California

David Botstein, PhD
Director, Lewis-Sigler Institute for Integrative Genomics
Evan B. Eichler Professor of Genomics
Princeton University
Princeton, New Jersey

Mark M. Davis, PhD
Investigator, Howard Hughes Medical Institute
Director of the Stanford Institute for Immunity, Transplantation and Infection
Stanford University School of Medicine
Stanford, California

Napoleone Ferrara, MD
Genentech Fellow
Molecular Oncology
Genentech, Inc.
South San Francisco, California

Sanjiv Sam Gambhir, MD, PhD
Director, Molecular Imaging Program
Head, Nuclear Medicine Division
Professor of Radiology and Bioengineering
Stanford University School of Medicine
Stanford, California

Todd R. Golub, MD
Investigator, Howard Hughes Medical Institute
Director of the Cancer Program of the Broad Institute
Charles A. Dana Investigator in Human Cancer Genetics
Dana-Farber Cancer Institute
Associate Professor of Pediatrics
Harvard Medical School
Boston, Massachusetts

Rachel Green, PhD
Investigator, Howard Hughes Medical Institute
Professor, Department of Molecular Biology and Genetics
The Johns Hopkins University
Baltimore, Maryland

Linda G. Griffith, PhD
Director, Biotechnology Process Engineering Center
S.E.T.T. Professor of Biological and Mechanical Engineering
Massachusetts Institute of Technology
Cambridge, Massachusetts

Greg Hannon, PhD
Investigator, Howard Hughes Medical Institute
Professor
Cold Spring Harbor Laboratory
Cold Spring Harbor, New York

Kenneth W. Kinzler, PhD
Professor of Oncology and Director
The Ludwig Center for Cancer Genetics and Therapeutics
The Johns Hopkins University
Kimmel Cancer Center
Baltimore, Maryland

Jacqueline A. Lees, PhD
Associate Director, David H. Koch Institute for Integrative Cancer Research
Ludwig Scholar
Professor of Biology
Massachusetts Institute of Technology
Cambridge, Massachusetts

Dan R. Littman, MD, PhD
Investigator, Howard Hughes Medical Institute
Helen and Martin Kimmel Professor of Molecular Immunology
Skirball Institute of Biomolecular Medicine
New York University School of Medicine
New York, New York

Kevan M. Shokat, PhD
Investigator, Howard Hughes Medical Institute
Professor and Vice Chair
Department of Cellular and Molecular Pharmacology
University of California, San Francisco

Elizabeth Yang, MD, PhD
Associate Professor of Pediatrics, Cancer Biology and Cell and Developmental Biology
Vanderbilt University Medical Center
Nashville, Tennessee

Sarkis K. Mazmanian, PhD
“Host-bacterial immunomodulation in the development of cancer” at the California Institute of Technology, Pasadena

John L. Rinn, PhD
“The functional roles of large intergenic non-coding RNAs in cancer” at the Beth Israel Deaconess Medical Center, Boston

Ivan Maillard, MD, PhD, and Yi Zhang, MD, PhD
“Modulation of Notch signaling to control graft-versus-host-disease and preserve the anti-tumor activity of alloreactive T cells” at the University of Michigan, Ann Arbor

David G. Kirsch, MD, PhD
“Transforming cancer therapy with molecular imaging” at Duke University Medical Center, Durham

WashinGTon
Muneesh Tewari, MD, PhD
“Cancer detection in ‘pre-diagnosis’ blood samples via exosome-associated small RNAs” at the Fred Hutchinson Cancer Research Center, Seattle

*This program is supported by a founding grant from Andy and Debbie Rachleff.

Damon Runyon-Rachleff
Innovation Awards

CALIFORNIA
Nathanael S. Gray, PhD
“Identification of kinase substrates using selective irreversible crosslinkers” at the Dana-Farber Cancer Institute, Boston

WASHINGTON
Muneesh Tewari, MD, PhD
“Cancer detection in ‘pre-diagnosis’ blood samples via exosome-associated small RNAs” at the Fred Hutchinson Cancer Research Center, Seattle

*This program is supported by a founding grant from Andy and Debbie Rachleff.
Damon Runyon
Clinical Investigator Award Committee 2009

CHAIR
Richard J. O'Reilly, MD
Chair, Department of Pediatrics
Chief, Pediatric Bone Marrow Transplant Service
Claire L. Tow Chair in Pediatric Oncology Research
Memorial Sloan-Kettering Cancer Center
New York, New York
Frederick R. Appelbaum, MD
Director, Clinical Research Division Member, Fred Hutchinson Cancer Research Center
Head, Division of Medical Oncology
University of Washington School of Medicine
Seattle, Washington
Joseph R. Bertino, MD
Chief Scientific Officer
The Cancer Institute of New Jersey
Interim Director, The Stem Cell Institute of New Jersey
University Professor of Medicine and Pharmacology
UMDNJ-Robert Wood Johnson Medical School
New Brunswick, New Jersey
David P. Carbone, MD, PhD
Harold L. Moses Chair in Cancer Research
Ingram Professor of Cancer Research
Vanderbilt-Ingram Cancer Center
Vanderbilt University
Nashville, Tennessee
Dennis A. Carson, MD
Professor of Medicine
Director, Moores Cancer Center
University of California, San Diego
La Jolla, California
Bruce A. Chabner, MD
Clinical Director
Massachusetts General Hospital Cancer Center
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Patricia A. Ganz, MD
Professor, Schools of Medicine and Public Health
Director, Division of Cancer Prevention and Control Research
Jonsson Comprehensive Cancer Center
University of California, Los Angeles
Los Angeles, California
Philip D. Greenberg, MD
Director, Immunology Program Member, Fred Hutchinson Cancer Research Center
Professor of Medicine and Immunology
University of Washington
Seattle, Washington
Hedvig Hricak, MD, PhD
Chair, Department of Radiology
Carroll and Milton Petrie Chair
Memorial Sloan-Kettering Cancer Center
New York, New York
William G. Kaelin, Jr., MD
Investigator, Howard Hughes Medical Institute
Professor of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts
Drew M. Pardoll, MD, PhD
Director, Cancer Immunology Program
Sidney Kimmel Comprehensive Cancer Center
Sarphat Professor of Oncology
The Johns Hopkins University
School of Medicine
Baltimore, Maryland
Leslie L. Robison, PhD
Member, St. Jude Faculty
Chair, Epidemiology and Cancer Control
St. Jude Children's Research Hospital
Memphis, Tennessee
Louise C. Strong, MD
Professor of Cancer Genetics
Sue and Radcliffe Killam Chair
Chief, Section of Clinical Cancer Genetics
M.D. Anderson Cancer Center
The University of Texas
Houston, Texas
David A. Williams, MD
Chief, Division of Hematology/Oncology
Director, Clinical and Translational Research
Children’s Hospital Boston
Dana-Farber Cancer Institute
Leland Fikes Chair of Pediatrics
Harvard Medical School
Boston, Massachusetts

Leslie L. Robison, PhD
Member, St. Jude Faculty
Chair, Epidemiology and Cancer Control
St. Jude Children's Research Hospital
Memphis, Tennessee
Louise C. Strong, MD
Professor of Cancer Genetics
Sue and Radcliffe Killam Chair
Chief, Section of Clinical Cancer Genetics
M.D. Anderson Cancer Center
The University of Texas
Houston, Texas
David A. Williams, MD
Chief, Division of Hematology/Oncology
Director, Clinical and Translational Research
Children’s Hospital Boston
Dana-Farber Cancer Institute
Leland Fikes Chair of Pediatrics
Harvard Medical School
Boston, Massachusetts
Damon Runyon Clinical Investigator Awards

CALIFORNIA
John M. Timmerman, MD
Lilly Clinical Investigator
“Dendritic cell-based immunotherapy for lymphoma” with Steven M. Dubinett, MD, University of California, Los Angeles

COLORADO
Douglass K. Graham, MD, PhD
Novartis Clinical Investigator
“Novel biologically targeted therapy against the Mer receptor tyrosine kinase in the treatment of pediatric ALL” with James V. DeGregori, PhD, and Sue Gail Eckhardt, MD, University of Colorado Denver, Aurora

FLORIDA
Juan Carlos Ramos, MD
Genentech Clinical Investigator
“Resistance to interferon-based therapy in adult T-cell leukemia” with Glen N. Barber, PhD, and Joseph D. Rosenblatt, MD, University of Miami School of Medicine, Miami

ILLINOIS
Vu H. Nguyen, MD *
August M. Watanabe, MD, Clinical Investigator
“Organ-specific regulatory T cells as a targeted therapy for graft-versus-host disease” with Thomas F. Gajewski, MD, PhD, The University of Chicago, Chicago

MARYLAND
Patrick A. Brown, MD †
Lilly Clinical Investigator
“Translating FLT3 inhibition into improved outcome for high risk childhood leukemia” with Donald Small, MD, PhD, The Johns Hopkins University School of Medicine, Baltimore

ANDREA L. COX, MD, PhD †
“Analysis and manipulation of cross reactive immune responses to partial escape mutation in chronic Hepatitis C virus infection” with Drew M. Pardoll, MD, PhD, The Johns Hopkins University School of Medicine, Baltimore

MASSACHUSETTS
Rachael A. Clark, MD, PhD
“Reversing immune evasion in human squamous cell carcinomas of the skin” with Thomas S. Kupper, MD, Brigham and Women’s Hospital, Boston

Catherine J. Wu, MD
“Innate-targeted leukemia antigens for eradication of CML stem cells” with Jerome Ritz, MD, Dana-Farber Cancer Institute, Boston

Andrew T. Chan, MD, MPH
“Molecular imaging of colorectal neoplasia” with Charles S. Fuchs, MD, MPH, and Ralph Weissleder, MD, PhD, Massachusetts General Hospital, Boston

MICHIGAN
Ronald J. Buckanovich, MD, PhD
“Tumor endothelial cells as a therapeutic and diagnostic target in ovarian cancer” with Daniel F. Hayes, MD, and Max S. Wicha, MD, University of Michigan, Ann Arbor

JOEL H. RUBENSTEIN, MD
Gordon Family Clinical Investigator
“The epidemiology of adipokines in Barrett’s esophagus” with John M. Inadomi, MD, and Philip S. Schoenfeld, MD, University of Michigan Medical School, Ann Arbor

MINNESOTA
Andrew L. Feldman, MD *
“Investigation of IRF4 as a therapeutic target in T-Cell Lymphomas” with Stephen M. Arsell, MD, PhD, and Ahmed Dogan, MD, PhD, Mayo Clinic, Rochester

VASSILIKI KARANTZA-WADSWORTH, MD, PhD
“AutoapHy as a therapeutic target in breast cancer treatment” with Robert S. DiPaola, MD, LUMNUS-Robert Wood Johnson Medical School, New Brunswick

NEW JERSEY
Renier J. Brentjens, MD, PhD †
Lilly Clinical Investigator
“Adaptive therapy of B cell leukemias with genetically modified autologous T cells” with Michel Sadelain, MD, PhD, Memorial Sloan-Kettering Cancer Center, New York

PHILLIP G. FEBBO, MD
Lilly Clinical Investigator
“Mechanisms of doxorubicin resistance in metastatic prostate cancer” with Herbert Kim Lyerly, MD, and Joseph R. Nevin, PhD, Duke University Medical Center, Durham

NORTH CAROLINA
William Y. Kim, PhD *
Merck Clinical Investigator
“Molecular determinants of clinical response to EGFR inhibition in bladder cancer” with Charles S. Perou, PhD, University of North Carolina, Chapel Hill

CHRISTOPHER RYAN MILLER, MD, PhD *
Genentech Clinical Investigator
“Genomics-driven drug development for giloblastoma” with Charles M. Perou, PhD, and Terry Van Dyke, PhD, University of North Carolina, Chapel Hill

PENNSYLVANIA
Marcia S. Brose, MD, PhD
Siemens Clinical Investigator
“The emerging clinical role of genetics in the treatment and diagnosis of thyroid cancer” with Susan J. Mandel, MD, MPH, and Peter J. O’Dwyer, MD, University of Pennsylvania, Philadelphia

TENNESSEE
Christine H. Chung, MD
Lilly Clinical Investigator
“Gene expression-based outcome prediction in head and neck cancer” with David P. Carbone, MD, PhD, Vanderbilt University Medical Center, Nashville

WASHINGTON
Coleen S. Delaney, MD, MSc
Novartis Clinical Investigator
“Notch-mediated ex vivo expansion of cord blood progenitors for hematopoietic cell transplantation” with Irwin D. Bernstein, MD, and Frederick R. Appelbaum, MD, Fred Hutchinson Cancer Research Center, Seattle

Elae A. Mostaghel, MD, PhD
Genentech Clinical Investigator
“Defining and exploiting molecular mechanisms of androgen-metabolism for prostate cancer therapy” with Peter S. Nelson, MD, Fred Hutchinson Cancer Research Center, Seattle

John M. Page, MD, PhD
Lilly Clinical Investigator
“Radioimmunotherapy of CD45+ leukemias” with Oliver W. Press, MD, PhD, Fred Hutchinson Cancer Research Center, Seattle

This award program is supported by a founding grant from Eli Lilly and Company of $275 million, a $1.5 million grant from Siemens Medical Solutions, $900,000 grants from both Genentech, Inc. and Novartis Pharmaceuticals Corporation, and a $450,000 grant from Merck and Company.

The Continuation Grant Program is supported by the William K. Bowes, Jr., Foundation, and Connie and Robert Lurie.

* Initial Award
† Continuation Grant Recipient
Thank You to our Donors
July 1, 2008 – June 30, 2009

Your support makes it possible for us to continue to address one of the most complex and devastating diseases today. Your generosity, through direct and planned gifts, demonstrates your trust in the work we do and accelerates progress toward new treatments and cures. Below, we highlight a sample of the generous gifts of the past year.

The Island Outreach Foundation, after researching several cancer charities, chose to support our high-risk, high-reward Innovation Award by funding one of its recipients, starting this year.

Rear Admiral Julia Plotnick, a former Chief Nurse Officer and Assistant Surgeon General of the United States, is honoring her late husband by naming a Fellow in his memory.

Bequests and Estates once again played an important role in sustaining our work. Through the estates of two very generous individuals, Elsinore Machris Gilliland and George Trommer, the Foundation received close to $11 million this year.

The Howard Hughes Medical Institute, one of the nation’s most prestigious medical philanthropies, doubled its support of our Fellowship Award to $1 million annually – a strong endorsement of the quality of scientists we select.
The 2009 Damon Runyon Annual Breakfast honoring Richard T. Clark, Chairman, President and Chief Executive Officer of Merck and Co., Inc., raised $1.4 million. More than 250 guests heard from Joe Kernen, co-anchor of CNBC’s flagship morning program “Squawk Box” and current Damon Runyon scientists, John L. Rinn, PhD, and Christine H. Chung, MD, who described their important research projects.

Go Vertical Chicago, our annual Sears Tower climb, had more than 2,000 participants and raised $410,000 for cancer research. We are grateful to our loyal Go Vertical Chicago climbers, volunteers and donors who have made this event a success for seven years.

Damon Runyon Broadway Tickets sold more than 4,800 tickets, raising close to half a million dollars. These funds help support our administrative operations, enabling us to give 100% of all direct donations to cancer research. We are indebted to the Shubert Organization, Nederlander Productions, Jujamcyn Theaters and Disney Theatrical Productions whose long-standing partnerships make this possible.

Thanks again to the visionary companies that understand that the next breakthrough drugs will not happen without the fresh ideas of young physicians and scientists: Eli Lilly and Co., Merck and Co., Genentech, Novartis Pharmaceuticals and Siemens Medical Solutions.

Ways to Give

**PLAN FOR CANCER RESEARCH IN YOUR WILL OR TRUST** Throughout our history, approximately 20% of our support has come through bequests and trusts. Please remember us in your estate plans. There are many ways to meet the financial needs of your loved ones and provide for the charities you feel passionate about. For advice, please contact us.

**SPONSOR A SCIENTIST** By sponsoring an individual Damon Runyon scientist, you could play an active role in the development of future cancer treatments and cures. We will name the award for you, your family or in honor of someone you choose.

**ANNUAL AND MONTHLY GIVING** We rely on annual and monthly gifts to fund our research programs. You can donate by mail, by phone or via our secure website at www.damonrunyon.org. We also welcome securities, which may provide you with significant tax savings.

**TRIBUTES** Honor your friends and loved ones with a donation for birthdays, holidays, or for no particular reason at all! You can also make gifts in memory of those close to you. A special card will be sent on your behalf.

**ATTEND AN EVENT** We specialize in events that are high in content yet short on lengthy speeches. Join us, meet other informed supporters and have the chance to engage with Damon Runyon scientists.

**DAMON RUNYON BROADWAY TICKETS** Enjoy access to top “house” seats at Broadway shows and support cancer research. Gift certificates are available that allow your beneficiary to choose the show and date. Call 212.455.0550 or visit www.damonrunyon.org/broadway.

To learn more about ways to support the Damon Runyon Cancer Research Foundation contact us at 212.455.0500 or visit www.damonrunyon.org/donate.

**100% of all donations support scientific research.**

All administrative and fundraising expenses are paid through Damon Runyon Broadway Tickets and our endowment.
Named Awards

The following awards are funded by dedicated supporters of the Damon Runyon Cancer Research Foundation who have generously endowed an award in perpetuity or sponsored an individual Damon Runyon scientist:

FELLOWS

Angelo Family Fellow
Laura A. Banaszynski, PhD
The Rockefeller University
New York, New York

Marion Abbe Fellow *
Carolyn M. Phillips, PhD
Massachusetts General Hospital
Boston, Massachusetts

Berger Foundation Fellow
Katharina Schlacher, PhD
Memorial Sloan-Kettering Cancer Center
New York, New York

Robert Black Fellows
Lea A. Goentoro, PhD
Harvard Medical School
Boston, Massachusetts

Gianna Elena Hammer, PhD
University of California, San Francisco
San Francisco, California

Ken S. Lau, PhD
Massachusetts General Hospital
Boston, Massachusetts

David Q. Matus, PhD
Duke University
Durham, North Carolina

Cara T. Pager, PhD
Stanford University
Stanford, California

Sarah E. Siegrist, PhD
University of California, Berkeley
Berkeley, California

Alla A. Sigova, PhD
Whitehead Institute for Biomedical Research
Cambridge, Massachusetts

Yun Wu, PhD
Princeton University
Princeton, New Jersey

Blount Family Fellow
Nadya Dimitrova, PhD
Massachusetts Institute of Technology
Cambridge, Massachusetts

Nancy and Larry Bossidy Fellow
Kathryn E. Wellen, PhD
University of Pennsylvania
Philadelphia, Pennsylvania

Enrique Cepero, PhD, Fellow
Melissa J. Junttila, PhD
University of California, San Francisco
San Francisco, California

Leo and Lilyan Cole Fund Fellow
Jung-Min Kee, PhD
The Rockefeller University
New York, New York

Dennis and Marsha Dammerman Fellow *
Christopher A. Johnston, PharmD, PhD
University of Oregon
Eugene, Oregon

Fraternal Order of Eagles Fellow *
Adam G.W. Matthews, PhD
Massachusetts Institute of Technology
Cambridge, Massachusetts

Dale F. and Betty Ann Frey Fellow *
Erik W. Debler, PhD
The Rockefeller University
New York, New York

Conrad Hilton Fellow
Sarah E. Tully, PhD
The Scripps Research Institute
La Jolla, California

Howard Hughes Medical Institute Fellows
Orkun Akin, PhD
University of California, Los Angeles
Los Angeles, California

Jelena Bezbradica, PhD
Yale University
New Haven, Connecticut

Michelle M. Boehm, PhD
Princeton University
Princeton, New Jersey

Matthew F. Calabrese, PhD
St. Jude Children’s Research Hospital
Memphis, Tennessee

Jianfu (Jeff) Chen, PhD
University of Colorado Denver
Aurora, Colorado

Alexandra M. Deaconescu, PhD
Brandeis University
Worcester, Massachusetts

Ryan C. Heller, PhD
Massachusetts Institute of Technology
Cambridge, Massachusetts

Kristina M. Herbert, PhD
Yale University
New Haven, Connecticut

Thomas M. Huckaba, PhD
University of California, San Francisco
San Francisco, California

Daniel F. Jarosz, PhD
Whitehead Institute for Biomedical Research
Cambridge, Massachusetts

Simon Jenni, PhD
Harvard Medical School
Boston, Massachusetts

Chitra V. Kotwalliwaile, PhD
University of California, Berkeley
Berkeley, California

Liana F. Lareau, PhD
Stanford University
Stanford, California

Jared T. Nordman, PhD
Whitehead Institute for Biomedical Research
Cambridge, Massachusetts

Ilan Wapinski, PhD
Harvard Medical School
Boston, Massachusetts

Yu Wong, MD, PhD
Stanford University
Stanford, California

Shenqin Yao, PhD
Harvard University
Cambridge, Massachusetts

Rebecca Ridley Kry Fellow *
Akinyemi I. Ojesina, MBBS, PhD
Dana-Farber Cancer Institute
Boston, Massachusetts

Kenneth G. and Elaine A. Langone Fellow *
Elaine M. Youngman, PhD
University of Massachusetts Medical School
Worcester, Massachusetts

Connie and Bob Lurie Fellow *
Timothy O. Street, PhD
University of California, San Francisco
San Francisco, California

Merck Fellows
Danielle S.W. Benoit, PhD
University of Washington
Seattle, Washington

Lee Stirling Churchman, PhD
University of California, San Francisco
San Francisco, California

Philip O’Bryan Montgomery, Jr., MD, Fellow *
Michael J. Emanuele, PhD
Brigham and Women’s Hospital
Boston, Massachusetts

Herald L. Plotnick Fellow
Chuan-Hsiaun Huang, MD, PhD
The Johns Hopkins University
Baltimore, Maryland

Fayez Sarofim Fellow *
Heather M. Scoibie, PhD
Yale University School of Medicine
New Haven, Connecticut

Lallage Feazel Wall Fellow *
Ken Cadwell, PhD
Washington University
St. Louis, Missouri
Named Awards (continued)

Suzanne and Bob Wright Fellow *
Lu Bai, PhD
The Rockefeller University
New York, New York

CLINICAL INVESTIGATORS
Gordon Family Clinical Investigator
Joel H. Rubenstein, MD
University of Michigan Medical School
Ann Arbor, Michigan

August M. Watanabe, MD, Clinical Investigator
Vu H. Nguyen, PhD
The University of Chicago
Chicago, Illinois

A number of Clinical Investigators are named in recognition of generous support from Eli Lilly and Company, Genentech, Inc., Siemens Medical Solutions, Novartis Pharmaceuticals Corporation and Merck and Company. Please refer to page 19 for a list of those who hold this distinction.

* In perpetuity

DAMON RUNYON ADVISORS
The Damon Runyon Advisors act as special advisors to the Foundation in their areas of expertise and are committed to expanding awareness about our important work to the next generation of supporters.

Jill E. Bargonetti-Chavarria, PhD
Professor
City University of New York and Hunter College

Michael J. Bossidy
Managing Director
JPMorgan Securities, Inc.

Erica K. Evans
Senior Vice President
ING Investment Management

Karen Fang
Managing Director
Goldman, Sachs & Co.

Jeremy Lack, PhD
Vice-President
New Leaf Venture Partners

Henry Mannix III
Vice President
Kelso & Company

Gerald M. Marshall
President and CEO
AmeriEnterprises, Inc.

John M. Olivieri
Partner
White & Case LLP

Annemarie Schoepfer
Senior Partner, Planning
Ogilvy & Mather Worldwide

Premier Circle 2009
The Broadway Premier Circle is a group of committed Damon Runyon Broadway Tickets customers who have made a special donation to the Foundation and have priority access to our fantastic seats.

Mrs. Barbara Lieb Baumstein
Ms. Nadine E. Bognar
Ms. Mary L. Cunningham
Bonni Curran, MD
Ms. Dorothy D’Amato
Mr. and Mrs. James Emanuele
Ms. Mary Ann Frenzel
Mr. and Mrs. Eugene B. Glick
Ms. Penelope P. Harris
Mr. and Mrs. Robert L. Harteveldt
Mr. and Mrs. Michael M. Kassen
Mr. Gene A. Kelly

Mr. and Mrs. James H. Kimerer
Mr. W. Loeber Landau
Mr. Joseph Leff
Mr. Joseph Mannello
Mr. and Mrs. Gerald M. Marshall
Ms. Lisa McNerney
Mr. Charles H. Murphy III
Mr. and Mrs. Jordan Nager
Mr. and Mrs. Michael C. Palitz
Mr. and Mrs. Jules L. Plangere III
Mr. and Mrs. Douglas C. Rentfield-Miller

Mr. and Mrs. Ernest Scheiller, Jr.
Mr. and Mrs. Perry Schwartz
Mr. and Mrs. Theodore M. Serure
Mr. Joseph M. Siegman
Mr. and Mrs. Henry J. Singer
Mr. and Mrs. Kenneth M. Stabler
Mrs. Barbara W. Stern
Mr. and Mrs. John S. Suhler
Mr. J. Ronald Terwilliger
Mr. Scott Undang
Mr. and Mrs. Peter J. Wasserman
Mrs. David A. Weir

Discovery Society 2009
The Discovery Society is a special group of individuals who have provided for the Damon Runyon Cancer Research Foundation through planned gifts. Over our history, the Foundation has received more than 2200 donations from individuals who made gifts through their estates.

Ms. Elaine M. Addis
Ms. Ann H. Cote
Mrs. Phyllis Farleigh
Robert F. Fisher, PhD
Ms. Mary Ann Frenzel
Mr. Rick J. Govern
Mr. and Mrs. William C. Hines

Mrs. Rebecca R. Kry
Mr. and Mrs. Charles B. Marqusee
Mr. D.G. Mitchell
Ms. Martha R. Nortner
Mr. and Mrs. Ronald E. Parr
William M. Poindexter, Esq.
Mr. Seymour Rosenheck

Ms. Phoebe H. Showers
Estate of Robert P. Stitzberg
Mrs. Carol H. Stix
Estate of Rita F. Tenkin
Ms. Rose Vaccariello
Mr. and Mrs. Arthur Walker

23
Our Donors

The Damon Runyon Cancer Research Foundation acknowledges the generosity and support of the many individual, corporate and foundation donors who supported our brilliant researchers through gifts to the Foundation from July 1, 2008 to June 30, 2009.* Those whose total lifetime giving to Damon Runyon is $100,000 or more are highlighted. We are especially grateful to these extraordinarily generous and committed donors.

$1,000,000 OR MORE
Eli Lilly and Company
Estate of Elsinore Machris Gilliland
Howard Hughes Medical Institute
Estate of George Trommer

$100,000-999,999
Judy Angelo Cowen Foundation
Anonymous
Robert Black Charitable Foundation
William K. Bowes, Jr. Foundation
Estate of Adrienne & Harry Chamberlain
Leon & Toby Cooperman Foundation
Genentech, Inc.
Sally and Michael Gordon Independent Charities of America
Island Outreach Foundation
Estate of Linda Jellenk
Merck & Company, Inc.
Novartis Pharmaceuticals Corporation
Mrs. Julia R. Plotnick
Rachleff Innovation Fund
Select Equity Group
Siemens Corporation
Estate of Rita F. Temkin

$50,000-99,999
Bank of America Corporation
Beacon Capital Partners, LLC/
Alan M. Leventhal
So& Margaret Berger Foundation
Leo W. & Lilian E. Cole Fund
Mr. and Mrs. Kenneth G. Langone
Vital Projects Fund, Inc.
Estate of Robert V. Werner

$25,000-49,999
Estate of Raymond E. Anderson
Angelo, Gordon & Co.
Maverick Capital Managers LLC
Barney Family Foundation
Bossidy Foundation
Estate of Rita Eisenberg
Ms. Margaret A. Gilliam
Grand Aerie Fraternal Order of Eagles
Estate of Elizabeth M. Gunn
Hettinger Foundation
J.P. Morgan Chase & Company
The Mel Karmazin Foundation Inc.
Marcus Foundation, Inc.
Pequot Capital Foundation
Joel E. Smilow Charitable Trust
Starr Foundation

$10,000-24,999
Mrs. Carolyn R. Aller
The Estate of Mr. Robert H. Allison
Anonymous
Anonymous
Caxton Associates, LLC
Mr. and Mrs. Kevin T. Conway
Dewey & LeBoeuf LLP
The Diller – von Furstenberg Family Foundation

Mr. and Mrs. Frank Doyle
Echlin Foundation
Ernst & Young
Betty Ann and Dale Frey
Fried, Frank, Harris, Shriver & Jacobson
General Electric Asset Management, Inc.
General Electric Foundation
Goldman, Sachs & Company
Irma T. Hirschi Charitable Trust
Hughes, Hubbard & Reed
Mr. and Mrs. Jay Ireland
David L. Lieb Foundation
Anthony F. Lofrisco, Esq.
Mr. and Mrs. Richard S. Loynd
Mandel Family Foundation
Mr. and Mrs. David G. Marshall
Estate of Gerald Martin
Gordon H. & Karen M. Miller
Family Foundation
Eugene & Mary Murphy Charitable Gift Fund
PricewaterhouseCoopers LLP
Mr. and Mrs. Robert P. Quinn
Louis and Rachel Rudin Foundation, Inc.
R.D. Scinto Corporation
SEFA of Maryland
Ms. Karen D. Setitz
Henry J. & Kathleen Singer Family Foundation
Barbara & Peter Strauss Philanthropic Fund
The T.F. Trust
Thomson Reuters Holdings, Inc.
Donald J. Trump Foundation, Inc.
Tzedschak Foundation
Ueberruth Family Foundation
Wachtell, Lipton, Rosen & Katz
Wickham Family Fund
Mr. Gary Wolf
Mr. and Mrs. Robert C. Wright
Young President’s Organization

$5,000-9,999
24 Hour Fitness Worldwide, Inc.
AlliedBarton Security Services
Almar Foundation
Howard Bayne Fund
Mr. and Mrs. Steven H. Berg
Mr. and Mrs. Richard L. Bowen
Estate of Rita Castellano
Community Health Systems, Inc.
Mr. and Mrs. James J. Costello
Creative Dimensions
Mr. and Mrs. Steven Einhorn
Mr. and Mrs. James Emanuele
Erichbaum Family Foundation
Fred Stein Family Foundation
Friedman Family Foundation
Mr. William Haber
Jennings Foundation
Johnson-Miller Foundation
Wm Maidman Family, L.P.
Mr. and Mrs. Henry Mannix III
Joe & Pasena Maroun Family Foundation
Trust
Mr. and Mrs. Gerald M. Marshall
Maverick Capital Charities, Ltd.
Ms. Lisa McNerney
Merrill Lynch & Company Foundation, Inc.
Dunlevy Milbank Foundation, Inc.
Sanford W. Morhouse, Esq.
Mr. and Mrs. Warren K. Myer
Mr. and Mrs. John H. Myers
Paisadle Capital Management, LLC
Mr. and Mrs. Roy Plum
Pyramid Hotel Group
Rain Foundation
Richard & Theresa Smith Memorial Fund
Gordon M. Ringold, PhD
Robert L. Nutt Charitable Foundation
Robertta & Scheller, Jr. Family Foundation
Stewart Senter, Inc.
Shamrock Holdings, Inc.
Ms. Suzy Sang Schechtman
Samuel C. Silverstein, MD
Mrs. Mikell M. Smith
Mr. and Mrs. Kenneth M. Stabler
Mr. James D. Staley
Mr. John L. Tishman
Thomas J. Watson Foundation
Estate of Winifred Wiederkern Worth Corporate Planning, Inc.

$1,000-4,999
AIG Matching Grants Program
Mr. Ben Alexander
Mr. Donald J. Allen
Altman Family Charitable Foundation
American Family Insurance
Mr. and Mrs. O. Kelley Anderson Jr.
Ms. Velma M. Anderson
Anonymous
Anonymous
Apple Lane Foundation
Ashfort Company
Mr. and Mrs. Kevin Ausbrook
Mr. Arthur S. Bahr
Jacqueline J. Bahr Foundation
Bank of America Foundation
Mr. F. Harlan Batus
Mr. and Mrs. Allen M. Bernkrant
Donald P. Bleik, PhD
Mr. and Mrs. Donald A. Bleznak
BLL Foundation
Mr. and Mrs. Robert G. Blount
The Boisi Family Foundation
Mr. and Mrs. Eugene K. Bolton
Mr. Thomas J. Bracken
Mr. William S. Brady
Mr. Max J. Budwick
Judy Buechner Advised Fund
Mr. and Mrs. Frank M. Burnstead
Steven J. Burakoff, MD
Mr. and Mrs. Arthur B. Calcagnini
Mr. and Mrs. Patrick J. Callan
Mr. and Mrs. William J. Campbell
Mr. and Mrs. Charles O. Carothers
Mr. and Mrs. Winifred Wiederkern
Mr. Mr. John L. Tishman
Thomas J. Watson Foundation
Estate of Winifred Wiederkern Worth Corporate Planning, Inc.

* Our donor lists are checked carefully. However, if you have any corrections or questions, please call 877-722-6237. The full pledge amount is listed in the year the pledge is made. In subsequent years, actual pledge payments are listed.
Financial Summary, Fiscal Year 2009

As in previous years the financial activities of the Foundation were audited by McGladrey and Pullen, LLP. For our complete audited financial statements please visit our web site at www.damonrunyon.org.

Overall Financial Health—Summary of Balance Sheets

Despite the economic crisis, the Damon Runyon Cancer Research Foundation remains financially strong. Because we have been able to grow our reserves over many years, we have been able to maintain our award programs at FY 2008 levels and have no current plans to reduce our commitment to the outstanding scientists we fund. However, like other organizations, the value of our investments, as well as those held in trust for us by others, declined.

<table>
<thead>
<tr>
<th></th>
<th>2009</th>
<th>2008</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Assets</td>
<td>82,223,404</td>
<td>96,418,937</td>
</tr>
<tr>
<td>Total Liabilities</td>
<td>15,249,307</td>
<td>15,592,947</td>
</tr>
<tr>
<td>Total Net Assets</td>
<td>66,974,098</td>
<td>80,825,989</td>
</tr>
</tbody>
</table>

Where Our Money Goes—Summary of Operating Expenses

TOTAL Operating Expenses $11.6 million
Where Our Support Comes From—Summary of Operating Revenue

Our sustained work depends on the generosity of individuals, corporations and foundations across the nation. We use a diversified fundraising approach that includes significant gifts to fund specific programs, events, annual giving, and our signature service, Damon Runyon Broadway Tickets, which, along with draws from our investments, allow us to continue to spend every dollar raised on vitally important cancer research.

Contributions $8.2 Million | Bequests and Trusts $.9 Million | Broadway Tickets $.5 Million | Draw from Investments $1.9 Million | Donated Services $.6 Million | TOTAL Operating Revenue $12.1 Million
“During our investigation of organizations involved in cancer research, we became intrigued with the work being done through Damon Runyon. Of particular interest was the Innovation Award program, which invests in individuals with high-risk, high-reward ideas that might not ordinarily be funded. Taking chances doesn’t always lead to success, but we believe it is well worth the investment in some of the brightest minds working on a most difficult challenge.”

The Island Outreach Foundation

“My husband of 41 happy years died in 2005 of metastatic cancer of the lung and brain. He had a very successful career as a university professor. We were both in ‘helping’ professions, Harold in social work and I in nursing. When I was deciding where to make a contribution in Harold’s memory, it seemed appropriate to fund research in cancer prevention and treatment that potentially will help many others to live longer, healthier lives.”

Julia R. Plotnick

“The fellowship that I received from the Damon Runyon Cancer Research Foundation gave me the opportunity to pursue my research passion in the lab of my dreams. It also allowed me to support my young family during those ‘postdoc years.’ Now, almost 20 years later, I can help support the next generation of scientists by giving back to the Foundation. My goal is to pay back my fellowship.”

Brian J. Stockman, PhD
Damon Runyon Fellow ’90–’91